Adaptimmune is a clinical stage biotechnology company with clinical trials ongoing for multiple proprietary SPEAR T-cells in solid tumor indications. Adaptimmune partners with industry leaders in all areas of its business.

The Company also has a strategic alliance with GlaxoSmithKline (GSK) in relation to its NY-ESO T-cell therapy program and up to four additional target programs.